Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + vincristine + dexamethasone
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A chemotherapy combination regimen consisting of cyclophosphamide, vincristine, and dexamethasone. This combination is primarily used in the treatment of androgen-independent prostate carcinoma (AI-PCa) and has shown efficacy with a favorable toxicity profile. The regimen typically involves oral cyclophosphamide (250 mg daily for days 1-14), intravenous vincristine (1 mg daily on days 1, 8, 15), and oral dexamethasone (0.75 mg twice daily for days 1-14) in 28-day cycles.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cyclophosphamide + vincristine + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + vincristine + dexamethasone.